Physical activity is associated with lower cerebral beta-amyloid and cognitive function benefits from lifetime experience-a study in exceptional aging.

Autor: Treyer V; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.; Department of Nuclear Medicine, University Hospital of Zurich, University of Zurich, Zurich, Switzerland., Meyer RS; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Buchmann A; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Crameri GAG; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Studer S; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Saake A; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Gruber E; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Unschuld PG; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.; Hospital for Psychogeriatric Medicine, Psychiatric University Hospital Zurich, Zurich, Switzerland., Nitsch RM; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.; Neurimmune, Schlieren-Zurich, Switzerland., Hock C; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.; Neurimmune, Schlieren-Zurich, Switzerland., Gietl AF; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2021 Feb 19; Vol. 16 (2), pp. e0247225. Date of Electronic Publication: 2021 Feb 19 (Print Publication: 2021).
DOI: 10.1371/journal.pone.0247225
Abstrakt: Background: Exceptional agers (85+ years) are characterized by preserved cognition presumably due to high cognitive reserve. In the current study, we examined whether personality, risk and protective factors for dementia as well as quality of life are associated with core features of Alzheimer's disease (amyloid-deposition and hippocampal volume) as well as cognition in exceptional aging.
Methods: We studied 49 exceptional agers (average 87.8 years, range 84-94 years), with preserved activities of daily living and absence of dementia. All participants received a detailed clinical and neuropsychological examination. We used established questionnaires to measure lifetime experience, personality, recent physical and cognitive activity as well as quality of life. Cerebral amyloid-deposition was estimated by 18-[F]-Flutemetamol-PET and manual hippocampal volumetry was performed on 3D T1 MRI images.
Results: In this sample of exceptional agers with preserved activities of daily living, we found intact cognitive performance in the subjects with the highest amyloid-load in the brain, but a lower quality of life with respect to autonomy as well as higher neuroticism. Higher self-reported physical activity in the last twelve months went with a lower amyloid load. Higher self-reported leisure-time/ not work-related activity went with better executive functioning at older age.
Conclusion: Even in exceptional aging, high amyloid load may subtly influence personality and quality of life. Our findings support a close relationship between high physical activity and low amyloid-deposition and underscore the importance of extracurricular activities for executive functions. As executive functions are known to be a central resource for everyday functioning in fostering extracurricular activities may be effective in delaying the onset of dementia.
Competing Interests: Valerie Treyer, Rafael S. Meyer, Andreas Buchmann, Giovanni A. G. Crameri, Sandro Studer, Antje Saake, Esmeralda Gruber, Paul G. Unschuld and Anton F. Gietl have nothing to disclose with respect to this publication. Since August 2018, Christoph Hock has assumed the role of Chief Medical Officer at Neurimmune AG, Schlieren, a spin-out of the University of Zurich, and Roger Nitsch has assumed the role of Chief Executive Officer of Neurimmune AG. Both Christoph Hock and Roger Nitsch are co-founders and board members of Neurimmune AG. Neurimmune AG develops therapeutic strategies against Alzheimer’s disease. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Databáze: MEDLINE
Externí odkaz: